Scientific white paper on concentration-QTc modeling.

Area of Science:

• Pharmacology and Drug Development
• Clinical Trial Design
• Biostatistics and Modeling

Background:

• The International Council for Harmonisation (ICH) E14 guideline revision permits concentration-QTc (C-QTc) modeling for drug QTc prolongation risk assessment.
• Early phase C-QTc modeling can serve as an alternative to thorough QT studies for certain drugs.

Purpose of the Study:

• To provide recommendations for planning and conducting definitive QTc assessments using C-QTc modeling in early clinical pharmacology and thorough QT studies.
• To outline best practices for study design, modeling objectives, and analysis reporting.

Main Methods:

• Utilizing C-QTc modeling as the primary analysis for QTc interval prolongation risk.
• Incorporating study design features from Phase 1 studies.
• Applying pre-specified linear mixed-effects models and evaluating model development.

Main Results:

• Demonstrates that well-designed C-QTc modeling in early studies can reliably exclude clinically relevant QTc effects.
• Establishes a framework for using C-QTc modeling as a primary analytical approach.

Conclusions:

• C-QTc modeling offers a viable and reliable alternative to traditional thorough QT studies for assessing drug-induced QTc prolongation.
• Recommendations are based on current best practices and are expected to evolve with further implementation and methodological advancements.